X

Stay Connected

Sign Up for Updates

We are creating a place where we can share ideas, provide the perspective of America's biopharmaceutical companies and, most importantly, listen to you.

Local Impact: Hepatitis C and Medicaid spending

By Priscilla VanderVeer  |    December 22, 2015
There has been a lot of discussion about the cost of new hepatitis C treatments to state Medicaid programs. What has not been addressed, however, is how those costs stack up against older, less...   Read More

Local Impact: State-by-state Medicaid spending on prescription medicines

By Rachel Licata  |    December 16, 2015
We’ve talked before about how prescription medicines comprise a small share of Medicaid spending. In recent years new life-changing, innovative medicines have come to market to help patients live...   Read More

Fact Check Friday: Medicaid spending on prescription medicines

By Allyson Funk  |    October 16, 2015
This week on Fact Check Friday, we’re talking about Medicaid. Medicaid provides health coverage for low-income and disabled individuals and is jointly funded by states and the federal government.    Read More

Local Impact: Improving diabetes care for children in Medicaid

By Samantha Dougherty  |    October 13, 2015
Earlier this fall we looked at how Medicaid beneficiaries adhering to their prescription drug regimens could result in a decline in expensive hospitalizations and emergency room visits, and...   Read More

Medicare Monday: Adherence in Medicare and Medicaid saves money

By Allyson Funk  |    September 14, 2015
If you’ve been following along with Medicare Monday, you’ve undoubtedly heard us talk about how adherence to prescription medicines helps save money in Medicare. Due to a growing body of evidence,...   Read More

Study: Better use of prescription drugs by Medicaid beneficiaries can yield significant savings

By Samantha Dougherty  |    September 9, 2015
If Medicaid beneficiaries adhered to their prescription drug regimens, they could significantly reduce U.S. medical costs, by reducing expensive hospitalizations and emergency room visits. A new...   Read More

GAO: Prescription Drugs Are Just 2% of Medicaid Spending

By Allyson Funk  |    August 5, 2015
Last week, the Government Accountability Office (GAO) released a detailed look at Medicaid and key issues facing the program. Despite rhetoric about the cost of prescription medicines in Medicaid,...   Read More

New Chart Pack: Biopharmaceuticals in Government Programs

By Allyson Funk  |    July 16, 2015
Today, PhRMA released a new resource on biopharmaceuticals in government programs. This new chart pack features key facts about prescription medicines in four major government programs – Medicare,...   Read More

Who Benefits from the 340B Drug Discount Program?

By Allyson Funk  |    June 10, 2015
The 340B program was created by Congress in 1992 to help vulnerable or uninsured patients gain access to needed prescription medicines, by requiring pharmaceutical manufacturers to provide steep...   Read More

340B Spotlight: A Look at 340B Purchases

By Karyn Schwartz  |    June 3, 2015
If you are familiar with the 340B program, you have probably heard the oft-cited assertion that 340B only represents 2% of pharmaceutical sales.[1] But just because a statistic is widely repeated,...   Read More

Search the Catalyst

View Posts by Topic

see all

Subscribe to Email Updates